The patient's performance status was used to determine the initial MTA dose at the discretion of the chief physician. Discontinuation and dose reductions were allowed based on tolerance. Adverse events were evaluated according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE), version 4.0.28, 29, 30 Treatment was discontinued when CTCAE grade ≥3 adverse events occurred.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.